Galantamine


Selective acetylcholinesterase inhibitor + alpha-7 nAChR PAM

A natural alkaloid from Galanthus and Narcissus species, FDA-approved as Razadyne for Alzheimer disease, distinguished by dual AChE inhibition and nicotinic receptor allosteric modulation.

Abstract

Galantamine (Razadyne, Reminyl; CAS 357-70-0; molecular formula C17H21NO3; molecular weight 287.36) is a tertiary amine alkaloid extracted originally from Galanthus nivalis (snowdrop) and Narcissus species, approved by the FDA in 2001 for mild-to-moderate Alzheimer disease and now produced synthetically. The compound is a selective reversible acetylcholinesterase inhibitor (Ki approximately 360 nM) with substantially weaker AChE inhibition than donepezil, but with a distinctive secondary mechanism that distinguishes it from other AChE inhibitors used clinically: galantamine is a positive allosteric modulator (PAM) of nicotinic acetylcholine receptors, particularly the alpha-7 and alpha-4-beta-2 subtypes most relevant to cognition. The dual mechanism produces a clinical profile considered slightly different from donepezil; some investigators report better effects on attention and behavioral symptoms. Pharmacokinetics: plasma half-life 7 hours; oral bioavailability essentially complete; metabolism is hepatic via CYP2D6 and CYP3A4. Schedule status: prescription-only but not federally scheduled.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph